Mar 18, 2026 06:33AM

Mar 17, 2026 08:30AM

Mar 17, 2026 08:30AM

Dec 16, 2025 03:57AM

Dec 15, 2025 07:30PM

Oct 8, 2025 12:58PM

Aug 8, 2025 12:20PM Aldeyra Therapeutics (ALDX) PT Raised to $9 at Jones Trading

Jul 17, 2025 07:02AM

Jul 17, 2025 07:00AM

Jun 17, 2025 07:02AM

Jun 17, 2025 07:00AM

Mar 17, 2025 05:18AM

Dec 16, 2024 06:47AM

Nov 18, 2024 07:04AM Aldeyra Therapeutics (ALDX) Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Nov 18, 2024 07:00AM

Oct 3, 2024 07:00AM

Oct 3, 2024 07:00AM

Feb 27, 2024 07:00AM

Oct 16, 2023 08:16AM

Aug 8, 2023 04:01PM

Jun 15, 2023 07:02AM Aldeyra Therapeutics (ALDX) Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis

Jun 15, 2023 07:00AM

May 4, 2023 07:00AM

Mar 9, 2023 07:00AM

Mar 2, 2023 07:00AM

Mar 2, 2023 07:00AM

Feb 7, 2023 07:01AM

Feb 7, 2023 07:00AM Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

15,418 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All